novo nordisk septerna

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Fierce Biotech · 2d

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Bloomberg on MSN · 2d

Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes in a deal potentially worth up to $2.2 billion.

PMLive2h

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

29m

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results